March 28, 2023 | Nora Samaranayake
Dr. Gallo Announces Transition Plans; Dr. Shyam Kottillil Named Interim Director
Robert C. Gallo, MD, one of the world’s leading virologists and cancer researchers, announced he has stepped down from his position as Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), effective March 24.
Dr. Gallo was Founding Director of the Institute when he and his colleagues established it in 1996, and holds the Homer & Martha Gudelsky Distinguished Professor in Medicine, Professor of Microbiology and Immunology. He now takes on the role as Director Emeritus of IHV and Special Advisor to the Dean at UMSOM before retiring next spring.
Shyam Kottilil, MBBS, PhD, of the Division of Clinical Care and Research Director at IHV, and Professor of Medicine and Chief of the Division of Infectious Diseases at UMSOM, will assume the role as Interim Acting Director of IHV.
Dr. Gallo is internationally renowned as a co-discoverer of HIV, the cause of AIDS, and as a two-time recipient of the prestigious Albert Lasker Award – a program established in 1945 to honor individuals who have made major contributions to medical science or who have performed public service on behalf of medicine. He received the first Lasker Award for Basic Science in 1982 for his discovery of the first human RNA tumor virus [the old name for retroviruses] and its association with certain leukemias and lymphomas. In 1986, he received the Lasker-DeBakey Clinical Medical Research Award for his co-discovery of the retrovirus now known as HIV-1 as the cause of AIDS.
"The foundation laid by Dr. Gallo and his co-founders, and nearly three decades of progressive scientific achievement since, have ensured IHV’s continued success and position as a global leader in the research of HIV/AIDS and other chronic viral diseases and cancer," said University of Maryland, Baltimore President Bruce E. Jarrell, MD, FACS.
Dr. Gallo established the Institute of Human Virology, the first-of-its-kind virology center that combines the disciplines of research, patient care, and prevention in a combined effort to speed the pace of medical breakthroughs and deliver care. Since its inception, the Institute has treated more than 2 million patients worldwide and approximately 5,000 patients each year for a variety of chronic and deadly viruses and immune disorders, most notably HIV. Prior to founding the institute, Dr. Gallo spent 30 years at the National Institutes of Health's National Cancer Institute, where he was head of its Laboratory of Tumor Cell Biology.
"Robert Gallo is a world-renowned scientist whose breakthrough discoveries and scholarly contributions have made major contributions to foundational science for more than four decades," said Mark T. Gladwin, MD, the John Z. and Akiko K. Bowers Distinguished Professor and Dean at the University of Maryland School of Medicine and Vice President, Medical Affairs at University of Maryland, Baltimore. "He is a visionary investigator who has unlocked many important mysteries of human viruses and diseases. Few living scientists have contributed so much to fundamental science, from the discovery of transfer RNAs, DNA polymerase, the first human retroviruses, the inflammatory cytokine interleukin-2, and the molecular basis for viral induced oncogenesis. He has been one of our most distinguished members of the University of Maryland School of Medicine faculty for many years and holds the unique distinction of twice winning America's most prestigious scientific award — the Albert Lasker Award in Medicine."
Dr. Gallo's legendary scientific career spans six decades. His major impact on scientific discovery began in the 1970s when he characterized all 61 types of the transfer RNAs in animal cells, which are used as essential adaptors when genetic messages are converted into proteins. Then, with a coworker, he described in human cells the enzyme that makes copies of DNA, known as DNA polymerase. In 1976, he identified the first cytokine, which is a chemical messenger that activates the immune system. This cytokine, Interleukin-2, first allowed researchers to grow T-cells in the laboratory and later was used to develop cancer immunotherapy.
"Bob Gallo has had an unparalleled impact on our understanding of the inner workings of infectious agents that afflict humans. The breadth and importance of his discoveries are astounding. There have been tremendous advances in the war on HIV/AIDS and without Bob’s contributions, we would not be where we are today," said Mario Stevenson, PhD, Professor of Medicine, Chief of the Division of Infectious Diseases, Director of the Institute of AIDS at the University of Miami Miller School of Medicine and Chair of IHV’s Scientific Advisory Board. "His vast impact on our scientific understanding cannot be understated."
In 1980, Dr. Gallo and colleagues discovered the first retrovirus, Human T-Cell Leukemia Virus-1 (HTLV-1) also the first virus shown to directly cause cancer without co-factors. Two years later, he identified a second retrovirus HTLV-2. These initial retroviral discoveries paved the way for identifying HIV. In 1986, he discovered the first new human herpes virus in more than 25 years, HHV-6, which causes roseola infantum, a fever and rash in infants, and possibly involved in some dementia.
In 1985, Dr. Gallo and his team developed the first HIV blood test, which has been updated by him and other over the years, allowing patient diagnoses and screening of blood used for transfusions. Dr. Gallo and his colleagues were important participants in an NCI-led project with the Burroughs Wellcome Fund developing the antiretroviral drug AZT as the first AIDS therapy.
In the early 2000s, Dr. Gallo and his colleagues at IHV developed an HIV vaccine candidate that has now progressed to a Phase Ib clinical trial in Thailand, a true example of IHV’s bench-to-bedside mission.
Most recently with the onset of the COVID-19 pandemic, Dr. Gallo along with colleagues, including Dr. Kottilil authored two studies that suggested that the oral polio vaccine made from a live, weakened virus may protect people from SARS-CoV-2. These findings suggest that these types of vaccines could be used in a pinch to protect from future pandemics by amping up the body’s first-response innate immune system.
Dr. Gallo received his BA Degree in Biology from Providence College and his MD Degree from Jefferson Medical College. After conducting his Clinical Clerkship at Yale University School of Medicine, he completed his residency at the University of Chicago.
Through his research legacy, Dr. Gallo has published more than 1,300 scientific papers and a book "Virus Hunting - AIDS, Cancer & the Human Retrovirus: A Story of Scientific Discovery," which has been published in 12 languages. Dr. Gallo was the most cited scientist in the world from 1980-1990 and was ranked third in the world for scientific impact during 1983-2002.
In 1996, Science magazine named his team’s work Breakthrough of the Year for demonstrating that certain cytokines could inactivate the HIV virus. He holds 35 honorary doctorate degrees. A sampling of his most prestigious international awards includes Canada’s Gairdner Foundation International Award; The Japan Prize of Science and Technology; Germany’s Paul Ehrlich and Ludwig Darmstaedter Prize; India’s Birla Prize; France’s Griffuel Prize; Spain’s Prince Asturias Award; Israel’s Dan David Award, the first Otto Herz Cancer Prize, and the Rabbi Shacknai Immunology Prize; Italy’s Premio International Award, International Science Prize, the Magna Graecia International Prize, and Tevere Roma International Award; China’s highest award, the VCANBIO Award for International Cooperation Life Sciences and Medicine; and the World Health Award from former Soviet Union President Gorbachev.
Dr. Gallo continues his investigation on the viral origins of some human cancers along with revealing more details on how HIV causes disease, focusing on one-day reaching a functional cure in which patients no longer need lifelong therapy.
His legacy will be celebrated at the 25th IHV Anniversary Celebration Gala & Symposium on September 28-29, 2023, at the Four Seasons Hotel in Baltimore, MD.
About the Institute of Human Virology
Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland, and the University of Maryland Medical System, the IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology, and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders, most notably HIV, the virus that causes AIDS. For more information, visit ihv.org and follow us on Twitter @IHVmaryland.
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world — with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
Contact
Nora Samaranayake
Chief Communications & Public Affairs Officer
Institute of Human Virology at the
University of Maryland School of Medicine
725 W Lombard St., S307
Baltimore, MD 21201
NSamaranayake@ihv.umaryland.edu
(410) 706-8614
www.ihv.org @IHVmaryland
Related stories
Friday, November 17, 2023
Major Funding of Partnership for HIV/AIDS Progress (PFAP) Award from the National Institute of Health (NIH) Office of AIDS Research to the Research Initiative on Infectious Disease and Substance Use (RIIS)
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) received an annual award for $3 million funded by the NIH Office of AIDS Research. The PFAP award is projected to total approximately $9 million over four years. Principal Investigators are Elana Rosenthal, MD and Sarah Kattakuzhy, MD, MPH.
Monday, October 31, 2022
NCI Grants Awarded to IHV to Prevent Cancer and Improve Screening in Sub-Saharan Africa
Institute of Human Virology (IHV) researchers at the University of Maryland School of Medicine (UMSOM) have received two five-year awards from the National Institutes of Health’s National Cancer Institute (NCI) for a total of $7.5 million. One award aims to reduce the incidence of lung cancer and other cancers associated with using tobacco in Botswana. The other is focusing on improving screening and treatment of anal precancer in Nigeria. Both grants will make use of existing HIV treatment and prevention infrastructure in low- and middle-income countries to reach people living with HIV who are most at risk for these particular types of cancers.
Tuesday, April 12, 2022
'Live' Polio Vaccine Fires Up Immune System Providing Protection from SARS-CoV-2 Infection
Two new studies from the Global Virus Network, including the University of Maryland’s Institute of Human Virology and in partnership with the Petroleum Industry Health Organization of Iran, provide evidence that getting the oral polio vaccine made from live, weakened polio-virus may protect people from COVID-19 infection by stimulating the immune system.
Tuesday, February 15, 2022
Multi-Country African Research Reports High Rates of COVID-19-Related Deaths Among Hospitalized Children and Adolescents
African children and adolescents hospitalized with COVID-19 experience much higher mortality rates than Europeans or North Americans of the same age, according to a recently published study conducted by researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and the Institute of Human Virology Nigeria (IHVN). Both organizations are members of the Global Virus Network (GVN).
Wednesday, December 01, 2021
$6.5M Grant Awarded to Develop Treatment for Alcoholic Liver Disease-Associated Kidney Dysfunction
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and MitoPower LLC (“MitoPower”) were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institute on Alcohol Abuse and Alcoholism. The funds will support the development of MitoPower’s lead compound, MP-04, for the treatment of kidney dysfunction due to alcoholic liver disease, a condition known as alcoholic liver disease-associated hepatorenal syndrome (HRS). The IHV, a Center of Excellence member of the Global Virus Network (GVN), will conduct first-in-human single and multiple ascending dose studies to test the safety of the compound, followed by a Phase 1b study in patients.
Tuesday, March 30, 2021
USA Today Opinion: Why COVID-19 survivors should only get one dose of mRNA vaccine
Data seems to be indicating that survivors of COVID-19 may not need two doses of mRNA vaccine, which would free up more doses for others.
Tuesday, March 16, 2021
ABC7 WJLA - 7 On Your Side: Doctor rates COVID-19 risks for activities in a partially-vaccinated world
“We see people come in, it's still with really severe disease,” said Dr. Eleanor Wilson, an infectious disease specialist and an associate professor of medicine at the Institute of Human Virology at the University of Maryland School of Medicine.
Thursday, February 04, 2021
WTOP NEWS: What a new U.Md. study says about skipping second doses of COVID-19 vaccine
None of the trials conducted on the Moderna and Pfizer-BioNTech vaccines tested them on people who already had been infected by the coronavirus. Now, a study involving people previously infected with COVID-19 suggests the immune response from getting sick may act like getting a first dose of those double-shot vaccines.
Tuesday, February 02, 2021
Business Insider: People who had COVID-19 may develop 10 times more antibodies after a single vaccine dose - a sign they might only need one shot
Business Insider - People who had COVID-19 developed at least 10 times more antibodies after their first vaccine dose than the average uninfected person who received two doses, new research shows. Another preliminary study similarly found that healthcare workers who had COVID-19 responded to their first shot the way most people respond to their second. The researchers both suggested that post-COVID patients may only need one shot to sufficiently protect them from the disease again.
Monday, December 21, 2020
Robert Gallo of the UM School of Medicine Institute of Human Virology and Global Virus Network Awarded Top Life Sciences and Medicine Prize from China
Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the Institute Human Virology at the University of Maryland School of Medicine and co-founder and international scientific advisor of the Global Virus Network, was awarded the “VCANBIO Award for Biosciences and Medicine,” a significant and authoritative award in the life sciences and medicine field of China. The elite Prize is jointly presented by the University of Chinese Academy of Sciences and the VCANBIO CELL & GENE ENGINEERING CORP, LTD to push forward scientific research, technological innovation and continuous development in the life sciences and medicine field of China.
Tuesday, December 15, 2020
UMSOM Institute of Human Virology’s Shyam Kottilil, MBBS, PhD Receives Top Award from National Physician’s Group
Shyam Kottilil, MBBS, PhD, professor of medicine at the University of Maryland School of Medicine (UMSOM), and Director of UMSOM’s Institute of Human Virology (IHV) Division of Clinical Care and Research, has been awarded Mastership in the American College of Physicians (ACP), the national organization of internists. Dr. Kottilil is also Chief of the Division of Infectious Diseases in the UMSOM Department of Medicine and is a scientific advisory member of the Global Virus Network (GVN).
Friday, December 11, 2020
Bloomberg TV Asia: Dr. Robert Gallo on COVID-19 Vaccines
Dr. Robert Gallo, co-founder and international scientific advisor of the Global Virus Network and the co-founder and director of the Institute of Human Virology at the University of Maryland School of Medicine, discusses the rollout of the Covid-19 vaccines. The first Covid-19 vaccine expected to be deployed in the U.S. won the backing of a panel of government advisers, a step that will likely help clear the way for emergency authorization by the Food and Drug Administration. Gallo, who co-discovered HIV as the cause of AIDS in 1984, speaks with Haidi Stroud-Watts and Shery Ahn on "Bloomberg Daybreak: Australia." (Source: Bloomberg)
Wednesday, November 11, 2020
Dr. Robert Gallo on Bloomberg Asia on COVID Vaccine Prospects
Dr. Robert C. Gallo, The Homer & Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the Institute of Human Virology at the University of Maryland School of Medicine and co-founder and international scientific advisor of the Global Virus Network, discusses the timeline and safety of Covid-19 vaccine trials. He speaks with Shery Ahn and Haidi Stroud-Watts on "Bloomberg Daybreak: Asia".
Monday, October 12, 2020
WJLA (Washington, DC): How long can you spread coronavirus once infected? We found out.
Social distancing, hand hygiene and face masks can help curb the spread of the highly contagious coronavirus but if you do get sick, how long can you spread COVID to others? 7 On Your Side went looking for answers.
Monday, August 31, 2020
UM School of Medicine’s Institute of Human Virology Recruits Top HIV/AIDS Epidemiologist Shenghan Lai Along with Team of Researchers
Robert C. Gallo, MD, the Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-founder and Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), and Man E. Charurat, PhD, MHS, Professor of Medicine, Director of the Division of Epidemiology & Prevention and CIHEB Global Director at the IHV, announced today that Shenghan Lai, MD, MPH and Hong Lai, PhD, MPH, in addition to three staff members, and two more to add, have joined the Institute of Human Virology. The faculty began their positions on April 1 with Professor and Associate Professor academic appointments in the UMSOM’s Department of Epidemiology & Public Health.
Friday, August 28, 2020
WYPR: Could Polio Vaccine Corral Covid-19?
A safe, effective vaccine against Covid-19 could resurrect jobs, send kids back to classrooms--change our lives. But how safe and effective? And how quickly can we have it? Dr. Robert Gallo, the AIDS-research pioneer now leading virus science at the Institute of Human Virology at the University of Maryland School of Medicine and the Global Virus Network, argues we could get much of the benefit by inoculating people with an old, very cheap drug -- the oral Polio vaccine developed seven decades ago. Gallo contends it would trigger our ‘innate immunity’-- the body’s emergency response when a threat shows up.
Friday, July 24, 2020
A Statement from the Leadership of the Institute of Human Virology and the Global Virus Network on the Passing of Renowned Chinese Virologist Yi Zeng
The IHV at the University of Maryland School of Medicine and the Global Virus Network (GVN), a coalition comprised of the world’s preeminent human and animal virologists from 55 Centers of Excellence and 10 Affiliates in 32 countries, collectively mourns the passing of Professor Yi Zeng, MD, Academician of the Chinese Academy of Sciences, former President of the Chinese Academy of the Preventive Medicine and former Dean of the College of Life Science and Bioengineering at Beijing University of Technology.
Wednesday, April 22, 2020
Dr. Robert Gallo Featured on National Geographic’s “Jane Goodall: The Hope” on 50th Anniversary of Earth Day
For the 50th anniversary of Earth Day on April 22, 2020, the National Geographic channel will broadcast back-to-back premieres of Photo Ark: Rarest Creatures and Jane Goodall: The Hope.
Saturday, April 11, 2020
Institute of Human Virology Honors Legacy of Maeve Kennedy McKean With Global Public Health Fellowship
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today the Maeve Kennedy McKean Global Public Health Fellowship, named in honor of the public health activist, whose inspiring life ended tragically alongside her oldest son last week. The first fellow will arrive on July 1 and will work on the Institute’s efforts in ending the HIV epidemic in Africa within its Center for International Health, Education, and Biosecurity (CIHEB) and Division of Clinical Care and Research.
Thursday, March 21, 2019
IHV Experts Researching Experimental Drug to Curb Opioid Cravings
Researchers at the University of Maryland School of Medicine (UMSOM) Institute of Human Virology (IHV) are collaborating with scientists at the National Institutes of Health to test an experimental drug to curb opioid cravings.
Wednesday, March 06, 2019
UMSOM Researcher Elected as Fellow to American Academy of Microbiology
Richard Y. Zhao, Ph.D., Professor of Pathology and Associate Member of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), has been elected as a Fellow to the American Academy of Microbiology (AAM). AAM is an honorific leadership group within the American Society for Microbiology (ASM).
Tuesday, December 11, 2018
Institute of Human Virology's Shyam Kottilil to Receive National Award from American College of Physicians
The American College of Physicians announced that Shyam Kottilil, MBBS, PhD, FACP, Professor of Medicine and Director of the Division of Clinical Care and Research at the Institute of Human Virology (IHV) of the University of Maryland School of Medicine (UMSOM) and Chief of the Division of Infectious Diseases, was awarded the American College of Physicians (ACP) Richard and Hinda Rosenthal Award #1 from the Rosenthal Family Foundation.
Tuesday, December 04, 2018
Institute of Human Virology Researchers Discover That a Bacterial Protein Promotes Cancer
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) announced today the discovery that DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell’s ability to respond to and repair DNA damage, a known origin of cancer.
Monday, December 03, 2018
Institute of Human Virology Names Dr. Man Charurat as Director of the Center for International Health, Education, and Biosecurity
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine today announced the appointment of Man E. Charurat, PhD, MHS, Professor of Medicine and Director of the Division of Epidemiology and Prevention at the IHV as the Director of IHV’s Center for International Health, Education, and Biosecurity (CIHEB). Dr. Charurat will replace Deus Bazira, DrPH, MPH, MBA. The announcement was made by Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director of the IHV, and Co-Founder and Director of the Global Virus Network (GVN).
Tuesday, October 23, 2018
Institute of Human Virology Hosts 20th Annual International Meeting of Top Medical Virus Researchers in Baltimore, Maryland
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine yesterday commenced IHV’s 20th Annual International Meeting, to be held through Thursday, October, 25 at the Four Seasons Hotel in Baltimore, Maryland. This year, among other viral and cancer related topics, the meeting is holding special sessions on the 40th anniversary of the first human retrovirus, Human T cell Leukemia Virus (HTLV), and the 15th anniversary of the President’s Emergency Plan for AIDS Relief (PEPFAR). IHV’s Annual International Meeting attracts hundreds of elite scientists who descend upon Baltimore to share ideas and inspire medical virus research collaborations.
Wednesday, September 19, 2018
Institute of Human Virology (IHV) Awarded $12M to Combat Opioid Epidemic Through Clinical Research Trials
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine will lead a $12 million dollar project to improve the morbidity and mortality of people with opioid use disorder (OUD). Utilizing a novel compound, IHV researches will implement a series of investigations, entitled SEARCH, to evaluate the underlying mechanisms of craving reduction as a strategy to prevent opioid misuse, dependence, and relapse. The grant is awarded through the National Institutes of Health’s (NIH) Helping to End Addiction Long-term (HEAL) Initiative, made possible through groundbreaking funding from the U.S. Congress.
Wednesday, March 21, 2018
Dr. Robert Redfield, Co-Founder of the Institute of Human Virology at the University of Maryland School of Medicine, to Become CDC Director
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) congratulates its co-founder and associate director, Robert R. Redfield, MD, on his appointment to be the next director of the U.S. Centers for Disease Control and Prevention (CDC).
Tuesday, March 20, 2018
UMSOM Cancer Expert at Institute of Human Virology Named Fellow of American Society of Clinical Oncology
Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS, Associate Director of Population Science at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMSOM), and Professor of Epidemiology and Public Health, Institute of Human Virology, has been named a 2018 Fellow of the American Society of Clinical Oncology (ASCO).
Tuesday, December 12, 2017
A Statement from the Leadership of the Institute of Human Virology on the Passing of Stewart Greenebaum
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine mourns the passing of Stewart Greenebaum, a lifelong Baltimore resident, former president of Greenebaum and Rose Associates, and past chairman of the IHV Board of Advisors, as well as a guiding force in the establishment of the IHV at the University of Maryland, Baltimore.
Wednesday, November 29, 2017
To Mark World AIDS Day, Institute of Human Virology Releases Video on Dr. Robert Gallo
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) released a video on Dr. Robert Gallo, a trailblazer in HIV research, in advance of World AIDS Day, December 1. While many know Dr. Gallo for his pioneering work in AIDS research, the short video focuses on Dr. Gallo’s life and legacy in its entirety, including his pioneering discovery of human retroviruses.
Tuesday, November 22, 2016
IHV Awarded $138M to combat HIV/AIDS in Africa & Launches Center for International Health, Education, & Biosecurity
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today more than $138 million in multiple five-year grants awarded by the Centers for Disease Control and Prevention to combat HIV/AIDS in Kenya, Tanzania, Zambia, and Nigeria. The Institute concurrently announced the formation of the IHV Center for International Health, Education, & Biosecurity (CIHEB), and its newly appointed director, Deus Bazira Mubangizi, DrPH, MBA, MPH, Assistant Professor of Medicine, Director, Center for Health, Education, & Biosecurity, Institute of Human Virology, University of Maryland School of Medicine.
Tuesday, October 25, 2016
"A Call to End HIV/AIDS in America" IHV Director Dr. Robert Gallo's Op-Ed in the Huffington Post
As the new Administration is presented with great challenges facing the United States, one will be a longtime foe, the U.S. HIV/AIDS epidemic. Since President Barack Obama was elected in 2008, I have publicly called on our country’s leaders to utilize the largest global health initiative in history - the President’s Emergency Plan for AIDS Relief (PEPFAR) - as a model to address the U.S. epidemic.
Monday, August 22, 2016
Institute of Human Virology (IHV) Awarded $14.4M for HIV Vaccine Research
The Institute of Human Virology (IHV) announced a $14.4M grant from NIAID to advance HIV vaccine research to solve a major challenge: produce long-lasting antibodies to protect against HIV infection.
Wednesday, April 13, 2016
IHV Releases Data Supporting Community-Based Treatment Providers in Fight Against Hepatitis C
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine released data today at The International Liver Congress 2016 in Barcelona, Spain demonstrating that treatment for hepatitis C virus (HCV) can be provided safely and effectively within a community-based and non-specialist setting.
Thursday, March 10, 2016
UM SOM Establishes Two Endowed Professorships Through Private Gifts and Matching State Funds
University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that the School has been awarded matching funds from the Maryland Department of Business and Economic Development (DBED) as part of the Maryland E-Nnovation Initiative Fund program. The funds, when combined with private philanthropy, will enable UM SOM to establish two new endowed professorships – one in human virology and vaccine development, the other in surgical science and entrepreneurship.
Tuesday, December 01, 2015
A Statement from the Leadership of the Institute of Human Virology on World AIDS Day
Research enabled treatment to be developed for HIV/AIDS, allowing the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (which Dr. Gallo heads and co-founded with his colleagues Drs. William Blattner and Robert Redfield) to develop a promising HIV vaccine candidate, treat nearly 6,000 patients annually in Baltimore, and care for more than 1 million people in Africa and the Caribbean since 2004.
Tuesday, September 29, 2015
Institute of Human Virology Hosts International Meeting of Prominent AIDS Researchers
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine is hosting IHV’s 17th Annual International Meeting Sunday, September 27 through Wednesday, September 30 at the Baltimore Marriott Waterfront Hotel in Baltimore, Maryland.